Mankind Pharma Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release Q4FY26 & FY26".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported Q4FY26 revenue of INR 3,443 Cr, up 11.8% YoY with domestic revenue growing 13.4% to INR 2,886 Cr. Adjusted EBITDA margin expanded 400 bps YoY to 27.1% and PAT margin improved 230 bps to 16.2%. Diluted EPS for Q4 was INR 13.4, up 30.3% YoY. For FY26, full-year revenue stood at INR 14,278 Cr (up 17.0% YoY) with exports surging 34.5% to INR 2,061 Cr. However, FY26 PAT declined 3.4% to INR 1,938 Cr with PAT margin compressing 280 bps to 13.6%, and diluted EPS fell 5.7% to INR 46.3. Adjusted EBITDA margin for FY26 was 25.4%, down 50 bps from FY25. Cash flow remained healthy with CFO to EBITDA ratio at 89% in FY26.
Q4 showed strong operational performance with margin expansion and profit growth, but FY26 full-year results reveal margin compression and profit decline despite robust revenue growth, likely due to one-time costs and investment pressures.